These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
523 related articles for article (PubMed ID: 24257811)
1. Reviewing the ketamine model for schizophrenia. Frohlich J; Van Horn JD J Psychopharmacol; 2014 Apr; 28(4):287-302. PubMed ID: 24257811 [TBL] [Abstract][Full Text] [Related]
2. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine]. Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L Encephale; 2001; 27(1):53-9. PubMed ID: 11294039 [TBL] [Abstract][Full Text] [Related]
3. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Javitt DC Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858 [TBL] [Abstract][Full Text] [Related]
4. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Javitt DC; Zukin SR; Heresco-Levy U; Umbricht D Schizophr Bull; 2012 Sep; 38(5):958-66. PubMed ID: 22987851 [TBL] [Abstract][Full Text] [Related]
6. Modulation of thalamo-cortical activity by the NMDA receptor antagonists ketamine and phencyclidine in the awake freely-moving rat. Amat-Foraster M; Celada P; Richter U; Jensen AA; Plath N; Artigas F; Herrik KF Neuropharmacology; 2019 Nov; 158():107745. PubMed ID: 31445017 [TBL] [Abstract][Full Text] [Related]
7. Failure of NMDA receptor hypofunction to induce a pathological reduction in PV-positive GABAergic cell markers. Benneyworth MA; Roseman AS; Basu AC; Coyle JT Neurosci Lett; 2011 Jan; 488(3):267-71. PubMed ID: 21094213 [TBL] [Abstract][Full Text] [Related]
8. Ketamine Administration During the Second Postnatal Week Alters Synaptic Properties of Fast-Spiking Interneurons in the Medial Prefrontal Cortex of Adult Mice. Jeevakumar V; Kroener S Cereb Cortex; 2016 Mar; 26(3):1117-29. PubMed ID: 25477370 [TBL] [Abstract][Full Text] [Related]
9. Complex receptor mediation of acute ketamine application on in vitro gamma oscillations in mouse prefrontal cortex: modeling gamma band oscillation abnormalities in schizophrenia. McNally JM; McCarley RW; McKenna JT; Yanagawa Y; Brown RE Neuroscience; 2011 Dec; 199():51-63. PubMed ID: 22027237 [TBL] [Abstract][Full Text] [Related]
10. Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Holcomb HH; Lahti AC; Medoff DR; Cullen T; Tamminga CA Neuropsychopharmacology; 2005 Dec; 30(12):2275-82. PubMed ID: 16034443 [TBL] [Abstract][Full Text] [Related]
11. Role of N-Methyl-D-Aspartate Receptors in Action-Based Predictive Coding Deficits in Schizophrenia. Kort NS; Ford JM; Roach BJ; Gunduz-Bruce H; Krystal JH; Jaeger J; Reinhart RM; Mathalon DH Biol Psychiatry; 2017 Mar; 81(6):514-524. PubMed ID: 27647218 [TBL] [Abstract][Full Text] [Related]
12. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Anand A; Charney DS; Oren DA; Berman RM; Hu XS; Cappiello A; Krystal JH Arch Gen Psychiatry; 2000 Mar; 57(3):270-6. PubMed ID: 10711913 [TBL] [Abstract][Full Text] [Related]
14. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Jentsch JD; Roth RH Neuropsychopharmacology; 1999 Mar; 20(3):201-25. PubMed ID: 10063482 [TBL] [Abstract][Full Text] [Related]
15. Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia. Abram SV; Roach BJ; Fryer SL; Calhoun VD; Preda A; van Erp TGM; Bustillo JR; Lim KO; Loewy RL; Stuart BK; Krystal JH; Ford JM; Mathalon DH Mol Psychiatry; 2022 May; 27(5):2448-2456. PubMed ID: 35422467 [TBL] [Abstract][Full Text] [Related]
16. Is the acute NMDA receptor hypofunction a valid model of schizophrenia? Adell A; Jiménez-Sánchez L; López-Gil X; Romón T Schizophr Bull; 2012 Jan; 38(1):9-14. PubMed ID: 21965469 [TBL] [Abstract][Full Text] [Related]
17. Glutamatergic Deficits in Schizophrenia - Biomarkers and Pharmacological Interventions within the Ketamine Model. Haaf M; Leicht G; Curic S; Mulert C Curr Pharm Biotechnol; 2018; 19(4):293-307. PubMed ID: 29929462 [TBL] [Abstract][Full Text] [Related]
18. Schizophrenia-like GABAergic gene expression deficits in cerebellar Golgi cells from rats chronically exposed to low-dose phencyclidine. Bullock WM; Bolognani F; Botta P; Valenzuela CF; Perrone-Bizzozero NI Neurochem Int; 2009 Dec; 55(8):775-82. PubMed ID: 19651169 [TBL] [Abstract][Full Text] [Related]
19. Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Coyle JT; Basu A; Benneyworth M; Balu D; Konopaske G Handb Exp Pharmacol; 2012; (213):267-95. PubMed ID: 23027419 [TBL] [Abstract][Full Text] [Related]
20. N-methyl-D-aspartate receptor antagonist effects on prefrontal cortical connectivity better model early than chronic schizophrenia. Anticevic A; Corlett PR; Cole MW; Savic A; Gancsos M; Tang Y; Repovs G; Murray JD; Driesen NR; Morgan PT; Xu K; Wang F; Krystal JH Biol Psychiatry; 2015 Mar; 77(6):569-80. PubMed ID: 25281999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]